Stockscreener 앱 받기
3.07
4.07%
0.12
시장 영업 전:
3.17
0.10
+3.26%
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics (ACTU) price target decreased by 17.00% to 21.16 - MSN
Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1% - MarketBeat
Actuate Therapeutics announces public offering of common stock - MSN
Why did Actuate Therapeutics (ACTU) stock jump over 14% after hours? - MSN
Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - whbl.com
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $15 - Moomoo
HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU) - MarketBeat
H.C. Wainwright reiterates Buy on Actuate Therapeutics stock By Investing.com - Investing.com Canada
Actuate Therapeutics Inc - Reuters
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours? - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
HC Wainwright Issues Optimistic Estimate for ACTU Earnings - National Today
B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com
Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial doubled one-year survival in study - Stock Titan
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial - Nature
ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift By Investing.com - Investing.com Canada
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift - Investing.com
Activity Recap: Can Actuate Therapeutics Inc scale operations efficiently2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Published on: 2026-04-09 23:48:44 - baoquankhu1.vn
Aug Levels: Does Actuate Therapeutics Inc have consistent dividend growth2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Actuate Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Profit Review: Is Actuate Therapeutics Inc benefiting from innovation trendsWeekly Trade Analysis & Consistent Return Strategy Ideas - baoquankhu1.vn
Will Actuate (ACTU) Stock Beat Expectations | Price at $2.10, Down 15.32%Community Buy Signals - Newser
Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen - MarketBeat
ACTU Technical Analysis & Stock Price Forecast - Intellectia AI
Actuate Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mazar Andrew Paul - Moomoo
Aug Setups: Is Actuate Therapeutics Inc stock showing strong momentum2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz
Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com
Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN
Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget
0.14%
0.48%
자본화:
|
볼륨(24시간):